VYNE Therapeutics Inc.
VYNE · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $14,320 | $70,552 | $67,423 | $142,670 |
| - Cash | $19,346 | $22,047 | $28,209 | $19,926 |
| + Debt | $0 | $25 | $63 | $99 |
| Enterprise Value | -$5,026 | $48,530 | $39,277 | $122,843 |
| Revenue | $169 | $69 | $202 | $84 |
| % Growth | 144.9% | -65.8% | 140.5% | – |
| Gross Profit | $169 | $69 | $202 | $84 |
| % Margin | 100% | 100% | 100% | 100% |
| EBITDA | -$7,420 | -$7,536 | -$9,191 | -$12,770 |
| % Margin | -4,390.5% | -10,921.7% | -4,550% | -15,202.4% |
| Net Income | -$7,280 | -$5,755 | -$8,611 | -$12,022 |
| % Margin | -4,307.7% | -8,340.6% | -4,262.9% | -14,311.9% |
| EPS Diluted | -0.17 | -0.13 | -0.2 | -0.28 |
| % Growth | -30.8% | 35% | 28.6% | – |
| Operating Cash Flow | -$7,096 | -$10,803 | -$11,461 | -$8,999 |
| Capital Expenditures | $0 | $0 | $0 | -$117 |
| Free Cash Flow | -$7,096 | -$10,803 | -$11,461 | -$9,116 |